FDA Slams Dabur India OTC Plant With Nine Observations After Microbiological Falsification Discovery

Dabur India Limited received a nine-observation Form 483 following an FDA inspection of its over-the-counter drug manufacturing facility in Dadra and Nagar Haveli from January 12-16, 2026. The inspection, findings published May 26, documents what the agency describes as systematic CGMP violations spanning data integrity, cleaning validation, equipment usage documentation, and quality unit oversight.

The most damning finding: 100% of finished product microbiology results showed zero colonies. During the inspection, the FDA investigator personally observed microbial growth, including two plates rated too numerous to count. The agency characterized this as deliberate falsification.

Beyond single-result manipulation, repeated numerical patterns in replicate testing suggested data was fabricated rather than generated through actual analysis. The investigator noted this pattern across multiple product lines.

Equipment Logs Rewritten to Hide Cross-Contamination Risk

Records covering April 2024 through December 2025 showed deliberate revision. Equipment claimed as single-product dedicated was actually used for multiple US-marketed OTC products. Dabur rewrote logs to conceal this, a direct violation of contemporaneous record-keeping requirements, according to the FDA.

The consequences extended to cleaning validation. The line falsely labeled as dedicated operated multi-product without any cleaning validation study. The FDA specified this affects multiple OTC batches still within expiry.

Cleaning Validation Based Entirely on Visual Inspection

No quantitative residue limits were established anywhere in the facility. No parts-per-million criteria. No microbiological acceptance criteria. Direct surface sampling of equipment contact surfaces and hard-to-clean areas was not performed. Cleaning verification consisted solely of visual inspection.

This represents a fundamental failure to implement basic pharmaceutical manufacturing controls.

Quality Control Bypassed Entirely

Batch manufacturing and analytical records received no review or approval by the quality unit before product release. Investigators found mismatched test values between batch records and analytical notebooks, incorrect API quantities documented, and assay values swapped between third-party certificates of analysis and internal data.

Dabur did not initiate investigations into these discrepancies.

Facility Conditions Reveal Systemic Neglect

A live bird and bird droppings were found in the raw material warehouse, approximately 30 feet from packaging materials. An unidentified black substance covered more than 25% of ceiling surfaces in both raw material and finished drug product storage warehouses. Dock door gaps presented additional pest entry points.

Stagnant liquid remained in production hoses, creating ongoing microbiological contamination risks. Annual product quality reviews were not conducted for the majority of site products, violating the firm's own standard operating procedures.

What This Means for Manufacturing Engineers

This case illustrates cascading failure. Data falsification wasn't an isolated incident but appears embedded in facility operations. The absence of basic cleaning validation, quality unit oversight, and environmental controls suggests either deliberate circumvention or profound organizational failure to understand GMP requirements.

For engineers evaluating contract manufacturers or auditing facilities, the warning signs are clear: unblinded microbiology results, visual-only cleaning verification, and batch records without QC approval represent controllable risk factors.

Dabur had not publicly responded to the findings as of publication. Companies typically submit corrective action plans addressing Form 483 observations. Warning Letters follow when responses prove inadequate.

M4S TAKE

My take: capacity expansions signal confidence, but the real question is whether demand justifies the spend. I watch for follow-up announcements about utilization rates or new contracts. Without those, this is just capital allocation.

Simon McLoughlin